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Background: To evaluate the effect of two different alpha-1 adrenoceptor antagonists on lower urinary tract
symptoms in patients who underwent LDR-brachytherapy.
Methods: A total of 141 patients who had been clinically diagnosed with localized prostate cancer and underwent
LDR-brachytherapy were enrolled. Patients were randomized and allocated to two groups (silodosin 8 mg vs.
naftopidil 75 mg). The primary endpoint was a change in the international prostate symptom score (IPSS) at
3 months after seed implantation. Secondary endpoints included the recovery rate of IPSS at 12 months after seed
implantation, the change in IPSS and overactive bladder symptom score, uroflowmetric parameters, and frequency
volume chart (FVC). To determine independent variables that can predict IPSS recovery, logistic regression analysis
was carried out.
Results: The mean change in the IPSS at 3 months after seed implantation in both groups was ⊿10.6 (naftopidil)
and ⊿10.4 (silodosin), respectively. There was not a significant difference between the two groups (p=0.728). An
increase in urinary frequency and a decrease in total urinated volume and mean voided volume were observed in
FVC for 12 months after seed implantation. Multivariate analysis revealed that the urethral dose (UD30) was an
independent predictive parameter of IPSS recovery. Patients with UD30 < 200Gy showed a higher recovery rate of
IPSS at 12 months after seed implantation.
Conclusion: There was no significant difference of serial change in IPSS between silodosin and naftopidil during
the first year after seed implantation. A lower dose on the urethra was an independent predictor of IPSS recovery at
12 months after seed implantation.
Keywords: Prostate cancer, LDR-brachytherapy, Alpha-1 adrenoceptor antagonist, Urinary morbidity, Randomized
controlled studyBackground
Low-dose-rate brachytherapy (LDR-brachytherapy) is
one of the curative treatment modalities alongside rad-
ical prostatectomy or intensity modulated radiation ther-
apy (IMRT) [1-5]. The most common adverse events of
LDR-brachytherapy are urinary frequency and urgency* Correspondence: sendo@naramed-u.ac.jp
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unless otherwise stated.[6-8]. More than 50% patients show urinary frequency
and urgency for 6 months after seed implantation. Al-
though an alpha-1 adrenoceptor antagonist is used to
prevent and relieve these symptoms, the efficacy on
these adverse events has not been assessed sufficiently.
Three subtype alpha-1 adrenoceptors are alpha-1A,
alpha-1B and alpha-1D. Of these different subtypes,
alpha-1A and alpha-1D receptors are predominantly
found in the bladder and prostatic urethra [9]. Alpha-1
adrenoceptor antagonist is commonly used to improveThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Tanaka et al. Radiation Oncology  (2014) 9:302 Page 2 of 7the urinary condition of benign prostatic hypertrophy
(BPH). Among several alpha-1 adrenoceptor antagonists,
silodosin has a predominant affinity for the alpha-1A
subtype receptor, while naftopidil has affinity for the
alpha-1D subtype receptor. Patients who undergo LDR-
brachytherapy commonly receive an alpha −1 blocker to
prevent and treat their urinary adverse events.
In this study we evaluate the efficacy of two alpha-1
adrenoceptor antagonists for subtypes 1A and 1D in pa-
tients who underwent LDR-brachytherapy and present
the urinary adverse events.
Methods
Of 170 patients who were clinically diagnosed with lo-
calized prostate cancer (cT1c-2cN0M0) and underwent
LDR-brachytherapy between July 2007 and April 2010,
the 141 patients who provided written informed consent
were enrolled in this prospective randomized study. Pa-
tients were randomized to be allocated to two antagonist
treatment groups (silodosin: 8 mg per day vs. naftopidil:
75 mg per day) by irradiation modality (seed alone
vs. boost), neoadjuvant androgen deprivation therapy
(ADT), and pretreatment international prostate symp-
tom score (IPSS) as an adjustment factor. Medication
continued for at least 3 months after seed implantation,
or until the International Prostate Symptom Score
(IPSS) returned to the pretreatment score or less.
Patients in the monotherapy group were treated by
seed implantation alone at a prescribed dose of 160 Gy,
while patients who received external beam radiation
therapy (EBRT) in combination were treated at a pre-
scribed dose of 110 Gy. The target portion of EBRT was
determined one month after seed implantation, and the
patients received 45 Gy (in 25 fractions of 1.8 Gy per
fraction) using 10 MV photon energy. The clinical target
volume included both the entire prostate and the prox-
imal third of the seminal vesicles.
The primary endpoint was IPSS at 3 months after seed
implantation. The secondary endpoints were recovery
rate of IPSS at 12 months after seed implantation, IPSS
and overactive bladder symptom score (OABSS), max-
imum flow rate (Qmax) and voided volume and post
voided residual (PVR) on uroflowmetry, and 24-hour
urinary frequency and total and mean voided volume on
a frequency volume chart (FVC) [10]. Each score was
evaluated before seed implantation and at 1, 3, 6, and
12 months later. Recovery was defined as a return of the
IPSS to the pretreatment score or less.
The IPSS recovery rate was calculated using a Kaplan-
Meier curve. The difference was evaluated by the log-
rank test. The serial change of each parameter was
tested between the pretreatment score and each mea-
sured period by Wilcoxon signed rank test. The differ-
ence in inter-group comparison was tested by theMann–Whitney U test. Sample size calculations deter-
mined that 62 patients in each group would be needed
to detect at least a 25% difference of efficacy between
the two study groups with α equal to 0.05 and power
equal to 80%. The baseline characteristics between the
two groups were tested by the chi-square test for cat-
egorical variables and the Mann–Whitney U test for
continuous variables.
To elucidate the predictive parameters for return of
IPSS to the baseline level at 12 months after seed
implantation, we conducted both univariate and multi-
variate logistic regression analyses (stepwise selection
method) using clinical parameters (age, neoadjuvant
ADT, combination of EBRT, adjuvant ADT, prostate vol-
ume at post-dosimetry, IPSS at baseline, alpha-1 ad-
renoceptor antagonist) and postoperative dosimetric
parameters. The dosimetric parameters analyzed in this
study were minimal percentage of the dose and minimal
dose (Gy) received by 90% of the prostate gland (%D90/
D90), percentage of the prostate volume receiving 100%
and 150% of the prescribed minimal peripheral dose
(V100/150), minimal percentage of the dose and min-
imal dose (Gy) received by 30% of the urethra (%UD30/
UD30), minimal percentage of the dose and minimal
dose (Gy) received by 90% of the urethra (%UD90/
UD90), rectal volume (mL) receiving 100% of the pre-
scribed dose (R100) and biologically effective dose
(BED). BED was calculated to evaluate an independent
factor to predict IPSS return, and an α/β ratio of 2 was
used. The BED values of both seed implantation and
EBRT were summed for patients treated with EBRT.
Post-implant CT scanning and post-implant dosimetric
studies were performed by one radiation oncologist
(A.I.) at 1 month after seed implantation. The parame-
ters that showed univariate significance (p-value of less
than 0.10) were input into multivariate models.
All statistical analyses were performed using PASW
Statistics 17.0 (SPSS Inc., Chicago, IL, USA). All p values
of less than 0.05 were considered statistically significant.
The institutional review board approved this prospective
study, and informed consent was obtained from all
patients after explaining the aim and methods of this
study.Results
The patient characteristics are shown in Table 1. Each
variable of patient characteristics did not show signifi-
cant differences between the naftopidil and silodosin
groups. Among all 141 patients, there were 4 (2.8%) who
suffered acute urinary retention requiring an indwelling
urethral catheter (naftopidil group: 2 patients, silodosin
group: 2 patients). There was not a significant difference
in the incidence of acute urinary retention between the
Table 1 Patients characteristics
Variables Naftopidil (n=70) Silodosin (n=71) p-value
Age median (range) 72 (56–83) 70 (57–83) 0.216*
PSA (ng/mL) median range 6.5 (3.7-31.8) 7.2 (3.5-17.7) 0.421*
Duration of NeoADT (month) median (range) 4 (2–43) 4 (1–34) 0.640*
Prostate volume (mL) at impant median (range) 26 (8–42) 27 (10–48) 0.187*
IPSS at baseline median (range) 6 (0–17) 7 (0–23) 0.132*
OABSS at baseline median (range) 3 (0–8) 3 (0–10) 0.343*
No of needle/seeds median (range) 22 (15–30)/60 (40–90) 22 (16–30)/65 (35–90) 0.304/0.128*
Total activity (MBq) median (range) 875 (449–1314) 876 (438–1314) 0.221*
Stage T1c/T2a/T2b/T2c/T3a 38/25/6/1/0 37/28/4/1/1 0.813†
Gleason score −6/7/8-10 44/24/2 45/24/2 0.648†
Neoadjuvant ADT yes/no 20/50 21/50 1.000†
EBRT yes/no 17/53 17/54 1.000†
Pre use of alpha-1 antagonist yes/no 12/58 10/61 0.649†
Neo ADT: neoadjuvant androgen deprivation theraphy.
*Mann–Whitney U test.
EBRT: external beam radiation therapy.
†chi-square test.
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ary retention.
Post-dosimetric parameters are shown in Table 2.
There was not a significant difference (except prostate
volume at post-dosimetry) between the naftopidil and
silodosin groups
IPSS and OABSS
The mean change in IPSS at 3 months after seed im-
plantation in the two groups was ⊿10.6 in the naftopidil
group and ⊿10.4 in the silodosin group. There was not
a significant difference in the IPSS change between the
two groups (p=0.728). The recovery rate of IPSS wasTable 2 Post-dosimetric parameters
Naftopidil (n=70)
Median (range)
PV (mL) at postdosimetry 26.8 (13.8-47.0)
%D90 (%) 114.1 (91.8-144.5)
D90 (Gy) 169.0 (110.6-213.5)
V100 (%) 95.8 (80.2-99.5)
V150 (%) 60.9 (33.6-87.9)
UD30 (Gy) 204.0 (123.7-267.4)
%UD30 (%) 134.8 (96.1-172.9)
UD90 (Gy) 141.2 (92.7-176.8)
%UD90 (%) 95.8 (63.4-149.2)
R100 (mL) 0.01 (0.00-1.00)
BED (Gy2) 197.7 (154.3-253.2)
PV: prostate volume at post-dosimetry, %D90: minimal percentage of the dose rece
the prostate gland, V100/V150: percentage of the prostate volume receiving 100%
percentage of the dose and minimal dose (Gy) received by 30% of the urethra), %U
by 90% of the urethra, R100: rectal volume (mL) receiving 100% of the prescribed d39% in the naftopidil group and 36% in the silodosin
group 12 months after seed implantation. There was not a
significant difference between the two groups (p=0.569).
The time-dependent change in IPSS showed a similar
pattern in both groups (Table 3). A statistically signifi-
cant increase in IPSS appeared at 1 month after seed
implantation and lasted thereafter. The peak IPSS deteri-
oration was observed at 3 months after seed implantation
in both groups. Though IPSS moved to improvement at 6
and 12 months later, the mean IPSS was significantly
higher than the baseline value after 12 months in both
groups. The change pattern in OABSS with time was also
similar to that of IPSS in both groups. A significantSilodosin (n=71) p-value












ived by 90% of the prostate gland, D90: minimal does (Gy) received by 90% of
and 150% of the prescribed minimal peripheral dose, %UD30/UD30: minimal
D90/UD90: minimal percentage of the dose and minimal dose (Gy) received
ose, and BED: biologically effective dose.
Table 3 The serial change in mean value (SD) of IPSS and OABSS
Variable Baseline 1 month 3 months 6 months 12 months
IPSS (total)
Naftopidil (n=70) 6.8 (4.3) 15.5** (8.0) 17.4** (8.5) 13.5** (7.9) 9.8** (7.1)
Silodosin (n=71) 7.9 (5.5) 15.5** (9.5) 18.3** (9.1) 14.4** (7.9) 9.8** (7.2)
Total (n=141) 7.4 (5.0) 15.5** (8.7) 17.8** (8.8) 13.9** (7.9) 9.8** (7.1)
OABSS (total)
Naftopidil (n=70) 3.5 (2.2) 6.1** (3.4) 6.8** (3.8) 5.8** (3.2) 4.5** (3.0)
Silodosin (n=71) 3.4 (2.6) 6.2** (3.7) 6.4** (3.5) 5.2** (3.2) 4.0** (3.0)
Total (n=141) 3.4 (2.4) 6.2** (3.6) 6.6** (3.6) 5.5** (3.2) 4.3** (3.0)
Baseline vs. *p < 0.05, **p < 0.01.
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ation and lasted for 12 months in both groups (Table 3).
Uroflowmetric parameters
Voided volume remained at significantly decreased levels
for 12 months after seed implantation in both groups.
There was not a significant difference in voided volume
between the 2 groups after seed implantation, except at
baseline (260 mL in the naftopidil group vs. 209 mL in
the silodosin group). Qmax was also significantly de-
creased throughout 12 months, showing no marked dif-
ference between the two groups. On the other hand,
PVR increased significantly up to 6 months in both
groups. The PVR at 12 months after seed implantation
in the silodosin group was significantly greater than that
in the naftopidil group (Table 4).
Frequency volume chart
The total volume significantly decreased at 3 months
after seed implantation and this was maintained up to
12 months in both groups. A significant difference inTable 4 The serial change in mean value (SD) of uroflowmetr
Variable Baseline 1 month
Uroflowmetric parameters
Vioded Vol.(mL)
Naftopidil (n=70) 260 (129) 153** (95)
Silodosin (n=71) 209 (111) 151** (89)
Total (n=141) 236 (123) 152** (92)
Qmax (mL/s)
Naftopidil (n=70) 13.2 (6.0) 9.7** (4.4)
Silodosin (n=71) 12.1 (5.2) 9.4** (4.5)
Total (n=141) 12.6 (5.7) 9.6** (4.4)
PVR (mL)
Naftopidil (n=70) 19 (38) 36** (45)
Silodosin (n=71) 23 (27) 38** (36)
Total (n=141) 21 (34) 37** (41)
*p < 0.05, **p < 0.01.total urine volume was seen at 3 months between the
2 groups. The 24-hour urinary frequency showed a sig-
nificant increase during 12 months after seed implant-
ation. There was not a difference in the urinary
frequency between the two groups. The mean voided
volume significantly decreased during 12 months after
seed implantation without any statistical differences be-
tween the two groups (Table 5).
Predictive variables of IPSS recovery at 12 months after
seed implantation
We conducted univariate and multivariate analyses of
the prediction of IPSS recovery at 12 months after seed
implantation for the clinical parameters (age, neoadju-
vant ADT, combination of EBRT, adjuvant ADT, prostate
volume at post-dosimetry, IPSS at baseline, alpha-1 adre-
noceptor antagonist) and postoperative dosimetric pa-
rameters. The multivariate analysis demonstrated that
UD30 was an independent parameter predicting IPSS re-
covery at 12 months after seed implantation (Table 6).
Using the 200 Gy cut-off point of UD 30, patients withic parameters
3 months 6 months 12 months
141** (72) 155** (72) 185** (128)
128** (81) 144** (76) 172** (100)
135** (77) 150** (74) 178** (115)
8.8** (3.8) 8.9** (3.3) 11.4** (5.4)
8.7** (4.4) 9.5** (4.6) 11.0** (5.4)
8.7** (4.1) 9.2** (4.0) 11.2** (5.4)
32** (39) 34** (38) 25 (36)
52** (71) 37** (34) 35* (45)
42** (58) 35** (36) 30* (41)
Table 5 The serial change in mean value (SD) of frequency volume chart
Variable Baseline 1 month 3 months 6 months 12 months
Total volume (mL/day)
Naftopidil (n=70) 1915 (756) 1871 (745) 1782** (533) 1718** (652) 1687** (562)
Silodosin (n=71) 1777 (573) 1862 (610) 1569** (583) 1633** (634) 1652** (564)
Total (n=141) 1846 (672) 1866 (680) 1675** (576) 1676** (642) 1670** (561)
24-hour urinary frequency
Naftopidil (n=70) 9.2 (2.4) 12.0** (3.9) 12.6** (3.9) 11.4** (3.7) 10.0** (2.5)
Silodosin (n=71) 9.2 (2.4) 12.3** (3.5) 11.8** (3.1) 11.2** (3.6) 10.3** (3.2)
Total (n=141) 9.2 (2.4) 12.2** (3.7) 12.2** (3.5) 11.3** (3.6) 10.1** (2.9)
Mean voided vol (mL)
Naftopidil (n=70) 215 (84) 165** (66) 151** (60) 157** (58) 177** (71)
Silodosin (n=71) 199 (66) 159** (56) 140** (57) 153** (55) 168** (64)
Total (n=141) 207 (76) 162** (61) 145** (58) 155** (57) 173** (67)
*p < 0.05, **p < 0.01.
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covery at 12 months after seed implantation (p=0.002,
odds ratio=3.094, 95% C.I.: 1.503-6.367).
Discussion
LDR-brachytherapy has now become one of the defini-
tive treatment modalities for prostate cancer alongside
radical prostatectomy and IMRT, not only for low-risk
patients, but also for intermediate and high-risk patients
[11]. The decision making about the primary therapy for
localized and advanced prostate cancer depends on the
patients’ quality-of -life, their preferences, and the status
of urinary and bowel conditions before treatment. Most
patients experienced urinary disorders, especially urinary
urgency and frequency up to 6–12 months after seed
implantation [6-8]. It is an essential and important issue
to prevent urinary adverse events in patients who
undergo LDR-brachytherapy. Long ago, many investiga-
tors reported the efficacy of alpha-1 adrenoceptor antag-
onists to relieve postoperative urinary adverse events in
patients who had undergone LDR-brachytherapy.
There were three phase 3 studies of alpha-1 adreno-





PV at post-dosimetry (mL) 0.066 0.957
D90(Gy) 0.018 0.984
UD30(Gy) 0.008 0.986
Neo ADT: neoadjuvant androgen deprivation therapy, EBRT: external beam radiatio
prostate gland, UD30: minimal dose (Gy) received by 30% of the urethra.patients who had undergone LDR-brachytherapy [12-14].
First, Elshaikh et al. reported a randomized placebo-
controlled study on the prophylactic effect of tamsulosin
[12]. The mean IPSS at 5 weeks after seed implantation
was significantly lower in the tamsulosin group, but there
was not a significant difference in the acute urinary reten-
tion rate. Tsumura et al. conducted a direct comparison of
3 different types of alpha-1 adrenoceptor antagonists
(tamsulosin, silodosin, and naftopidil). They concluded
the superiority of alpha-1A antagonist to change the IPSS
compared with the alpha-1D antagonist [13]. Shimizu et al.
reported a controlled randomized study that compared a
super-selective alpha-1A adrenoreceptor antagonist group
with a control group. The change in IPSS at 6 months
after seed implantation and the change in the QOL score
at 3 months after seed implantation in the alpha-1A antag-
onist group were significantly smaller than those in the
control group. However, there was not a significant im-
provement in the bladder outlet obstruction index (BOOI)
in the silodosin group based on a pressure flow study [14].
On the other hand, the present study did not show a sig-
nificant difference in the IPSS change between the alpha-1A
antagonist group and the alpha-1D antagonist group.PSS recovery at 12 months after seed implantation
Multiivariate






n therapy, PV: prostate volume, D90: minimal dose (Gy) received by 90% of the
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plantation was seen in each study. Although a statistical
improvement in IPSS was seen, the substantial differ-
ence between these studies was clinically subtle. Alpha-1
adrenoceptor antagonists act effectively to relieve urinary
adverse events after seed implantation. However, the use-
fulness of these alpha-1 adrenoceptor antagonists has not
been clarified sufficiently.
A phase 3 study was conducted to investigate whether
anti-inflammatory treatment after seed implantation
was useful for to relieve the adverse symptoms of
brachytherapy [15]. They evaluated the effect of a
cyclooxygenase-2 (COX-2) inhibitor. A 4-week course
of meloxicam, starting either on the day of implant or
1 week prior to implant was evaluated. There was not a
significant difference between the 2 arms. The 1-month
edema of the prostate, IPSS at 1 and 3 months, and acute
urinary retention rate did not show any differences.
The present study is the first report of FVC data after
seed implantation. There were no obvious differences in
the total urination volume, frequency of urination, or
mean voided volume between the silodosin group and
the naftopidil group. Overall, the total urination volume
significantly decreased from 3 months up to 12 months
after seed implantation, and the frequency of urination
significantly increased up to 12 months after seed im-
plantation. On the other hand, the mean voided volume
significantly decreased up to 12 months after seed im-
plantation. These changes showed a similar result when
compared with IPSS and OABSS change as subjective
parameters and uroflowmetric variables (voided volume,
Qmax and PVR) as objective parameters.
We conducted multivariate analysis to predict the IPSS
recovery at 12 months after seed implantation. Finally,
the urethral dose (UD30) remained as a predictive par-
ameter, while the use of an alpha-1 adrenoceptor antag-
onist, the combination of EBRT, the use of neoadjuvant
androgen deprivation therapy, prostate volume, and the
dose to the prostate (D90) did not remain. A higher dose
to the urethra resulted in lower recovery of the IPSS
(Table 6). Furthermore, patients with UD 30 < 200Gy
showed a 3 times higher recovery rate in the IPSS
at 12 months after seed implantation (p=0.002, odds
ratio=3.094, 95% C.I.: 1.503-6.367). These results indi-
cated that the prevention of excessive urethral irra-
diation is an important task to relieve the urinary
condition of patients who undergo LDE-brachytherapy.Conclusion
Our present study could not detect any difference in
the IPSS change between 2 different types of alpha-1
adrenoceptor antagonists. We however revealed, for
the first time as far as we know, an increase in theurination frequency, and a decrease in the total urin-
ation volume and mean voided volume in the frequency
volume chart up to 12 months after seed implantation.
A lower dose to the urethra was an independent pre-
dictor of a higher recovery rate in the IPSS 12 months
after seed implantation.
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